Immunotherapy and chemotherapy before surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy and bevacizumab before surgery can shrink rectal tumors and improve outcomes. It is designed for people with locally advanced rectal cancer that has not spread to distant organs, and the treatment is given as a first step before the main surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 to 75 years old
- Must have a confirmed diagnosis of rectal adenocarcinoma, with the tumor located 5-12 cm from the anal verge
- Must have a tumor that is staged as cT3-4N0M0 or cTxN+M0 (locally advanced but not spread to distant organs)
- Must have a biopsy showing the cancer is pMMR or MSS (meaning it has intact DNA repair mechanisms)
- Must not have had any prior cancer treatment for this rectal cancer (radiation, chemotherapy, targeted therapy, or immunotherapy)
- Must have adequate organ function (blood counts, liver, kidneys, and blood clotting) and be fit enough to undergo surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This trial tests a combination of radiation, chemotherapy (CAPOX), and immunotherapy (iparomlimab and tuvonralimab) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy, targeted therapy, and immunotherapy, with or without radiation to the primary tumor, for people with advanced rectal cancer that has a specific genetic profile. It aims to see if adding radiation improves outcomes.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.